Federated Hermes Inc. Buys 2,882 Shares of iTeos Therapeutics, Inc. (NASDAQ:ITOS)

Federated Hermes Inc. lifted its stake in shares of iTeos Therapeutics, Inc. (NASDAQ:ITOS) by 4,648.4% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 2,944 shares of the company’s stock after purchasing an additional 2,882 shares during the period. Federated Hermes Inc.’s holdings in iTeos Therapeutics were worth $32,000 at the end of the most recent quarter.

Other large investors also recently made changes to their positions in the company. PNC Financial Services Group Inc. grew its position in shares of iTeos Therapeutics by 131.5% in the 3rd quarter. PNC Financial Services Group Inc. now owns 2,287 shares of the company’s stock valued at $25,000 after acquiring an additional 1,299 shares during the period. China Universal Asset Management Co. Ltd. lifted its stake in iTeos Therapeutics by 348.1% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 4,140 shares of the company’s stock valued at $45,000 after purchasing an additional 3,216 shares during the last quarter. Quantbot Technologies LP bought a new position in iTeos Therapeutics during the third quarter worth about $51,000. Zurcher Kantonalbank Zurich Cantonalbank increased its position in iTeos Therapeutics by 53.3% during the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 8,826 shares of the company’s stock worth $97,000 after buying an additional 3,069 shares during the last quarter. Finally, Amalgamated Bank raised its stake in iTeos Therapeutics by 14.7% in the 3rd quarter. Amalgamated Bank now owns 10,574 shares of the company’s stock valued at $116,000 after acquiring an additional 1,357 shares during the period. Institutional investors and hedge funds own 97.16% of the company’s stock.

iTeos Therapeutics Stock Performance

Shares of iTeos Therapeutics stock opened at $12.31 on Wednesday. The firm has a 50-day moving average of $11.58 and a 200-day moving average of $10.73. iTeos Therapeutics, Inc. has a 52-week low of $8.20 and a 52-week high of $18.24. The stock has a market cap of $442.79 million, a PE ratio of -3.91 and a beta of 1.27.

iTeos Therapeutics (NASDAQ:ITOS) last posted its quarterly earnings data on Wednesday, March 6th. The company reported ($0.85) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.03) by $0.18. Equities research analysts predict that iTeos Therapeutics, Inc. will post -4.76 earnings per share for the current fiscal year.

Analyst Ratings Changes

ITOS has been the topic of a number of research reports. HC Wainwright reiterated a “buy” rating and issued a $44.00 price target on shares of iTeos Therapeutics in a research note on Thursday, March 7th. Wedbush reiterated an “outperform” rating and set a $18.00 target price (down previously from $25.00) on shares of iTeos Therapeutics in a research note on Wednesday, March 6th.

iTeos Therapeutics Profile

Iteos Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients with cancer. The company's lead antibody product candidate, belrestotug, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial, as well as used to engage the Fc gamma receptor, or Fc?R to activate dendritic cells, natural killer cells, and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity.